[{"id":"1551fdea-4388-4abb-8e4a-606aa2a8d9a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03970382","created_at":"2021-01-18T19:31:43.454Z","updated_at":"2024-07-02T16:36:05.198Z","phase":"Phase 1a/1b","brief_title":"A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors","source_id_and_acronym":"NCT03970382","lead_sponsor":"PACT Pharma, Inc.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Proleukin (aldesleukin) • NeoTCR-P1"],"overall_status":"Suspended","enrollment":" Enrollment 21","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 08/12/2022","primary_completion_date":" 08/12/2022","study_txt":" Completion: 08/12/2022","study_completion_date":" 08/12/2022","last_update_posted":"2022-08-18"}]